10 July 2025
10 July 2025
The transaction will enhance Merck's cardio-pulmonary pipeline and portfolio with the addition of Ohtuvayre, an FDA-approved COPD treatment.
Despite the threat of a 200% tariff, most pharma stocks remained stable.
With artificial intelligence (AI) fast becoming an ubiquitous part of everyday life, its further application in clinical trials holds considerable promise.
The agreement will enhance the availability of Lupin’s biosimilar Certolizumab Pegol on a global scale.
Niagen Bioscience can either commercialise the drug candidate independently or sublicense to a strategic pharmaceutical partner.
In a more challenging regulatory environment for clinical trials, optimising trial designs early makes success more likely.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
